阿霉素是多種血液惡性腫瘤和實(shí)體瘤的主要治療藥物。然而，其臨床應(yīng)用受劑量相關(guān)性心臟毒性的限制。阿霉素誘導(dǎo)心臟毒性的機(jī)制可能涉及多種信號(hào)通路，包括自由基產(chǎn)生、鈣超載、線粒體功能障礙、細(xì)胞凋亡和自噬。已有研究表明白藜蘆醇與阿霉素聯(lián)合用藥可以預(yù)防心臟毒性，并且對(duì)腫瘤細(xì)胞發(fā)揮協(xié)同治療效應(yīng)。主要對(duì)白藜蘆醇的心臟毒性保護(hù)作用進(jìn)行綜述，闡明白藜蘆醇在阿霉素誘導(dǎo)心臟毒性中保護(hù)作用的機(jī)制。

Adriamycin is a major therapeutic agent for a variety of hematological malignancies and solid tumors. However, its clinical application is limited by dose-dependent cardiotoxicity. The mechanism of doxorubicin-induced cardiotoxicity may involve multiple signaling pathways, including free radical production, calcium overload, mitochondrial dysfunction, apoptosis and autophagy. Studies have shown that resveratrol combined with doxorubicin has been reported to prevent cardiac toxicity, and play a synergistic effect on tumor cells. The protective effect of resveratrol on cardiac toxicity is reviewed in this paper, and the protective mechanism of resveratrol in adriamycin-induced cardiotoxicity is also elucidated.